ConductScience.org, home

Trial · NCT00600002

Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

NCT00600002, Phase 1, Completed, Edward Nelson

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma. Trials, record NCT00600002. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00600002

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
NCT number
NCT00600002
Status
Completed
Phases
Phase 1
Enrollment
30 participants, actual
Lead sponsor
Edward Nelson
Conditions
Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
GM-CSF
First posted
2008-01-24
Last updated
2018-06-11

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryEvaluate toxicity, dendritic cell recruitment, and immune parameters2 years
SecondaryEvaluate patient survival2 years
SecondaryEvaluate progression free survival2 years
SecondaryEvaluate time to treatment failure2 years
SecondaryEvaluate quality of life2 years
SecondaryEvaluate biochemical markers2 years

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00600002

GET https://conductscience.org/api/trials/v1/NCT00600002/registered